MAP Insights

A more in-depth look at news, policies and developments. Insights from both our in-house team of consultants in policy, public affairs, health economics and market access, as well as a roster of external experts with a wealth of knowledge and expertise.

Insights

A more in-depth look at news, policies and developments. Insights from both our in-house team of consultants in policy, public affairs, health economics and market access, as well as a roster of external experts with a wealth of knowledge and expertise.

The Health and Care Bill – what does it do and how will it affect the life sciences industry?
Published 28th July 2021

The Health and Care Bill had its Second Reading in the House of Commons on 14 July and is expected to become law in early 2022. This article explains the main purposes of the Bill and the potential implications for the life sciences industry.

Read more
The Health and Care Bill



NICE consultations on methods and processes – what they mean and next steps
Published 13th July 2021

The consultation of NICE methods in November 2020 was the first reassessment since 2013 and was widely welcomed. In February 2021, NICE began a review of the health technology evaluation processes. This article examines key issues related to each review and MAP’s response.

Read more
NICE consultations on methods and processes – what they mean and next steps



What does the Northern Ireland Protocol mean for the life science industry?
Published 29th June 2021

The conclusion of the Northern Ireland Protocol will have a direct effect on the life science industry who have current or potential sales to Northern Ireland.
This article gives an overview of the Protocol and answers some of the key questions that have arisen in recent weeks.

Read more
The vital importance of future EMA and MHRA relations for UK life sciences



The vital importance of future EMA and MHRA relations for UK life sciences
Published 24th May 2021

Since the 2016 Brexit vote, there has been considerable uncertainty around the future of drug and medtech regulation in the UK. This article explores the potential routes towards a mutual recognition agreement and how this could be achieved through representation by the life sciences industry.

Read more
The vital importance of future EMA and MHRA relations for UK life sciences



The NHS Commercial Framework and the options it provides
Published 11th March 2021

The NHS Commercial Framework for New Medicines has been published. It aims to support patient access to affordable and transformative medicines. MAP provides insights into the effect it will have on the industry going forward.

Read more
Analysis of the new NHS White Paper – Part 1



Analysis of the new NHS White Paper
Published 19th February 2021

The New NHS White Paper on reforming the NHS, Integration and Innovation: working together to improve health and social care for all, which was foreshadowed in MAP’s blog on 9 February, was published on 11 February.

Read more
Analysis of the new NHS White Paper – Part 2



CareersTerms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

 +44 (0) 1480 832360

 enquiries@mapbiopharma.com

MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281

VAT Group Registration Number:
GB 292 8576 52